OBJECTIVE: To evaluate whether the risks of herpes zoster (HZ) differed by biologic agents with different mechanisms of action (MOAs) in older rheumatoid arthritis (RA) patients. METHODS: Using Medicare data from 2006-2011, among RA patients with prior biologic agent use and no history of cancer or other autoimmune diseases, this retrospective cohort study identified new treatment episodes of abatacept, adalimumab, certolizumab, etanercept, golimumab, infliximab, rituximab, and tocilizumab. Followup started on initiation of the new biologic agent and ended at any of the following: first incidence of HZ, a 30-day gap in current exposure, death, a diagnosis of other autoimmune disease or cancer, loss of insurance coverage, or December 31, 2011. We calculated the proportion of RA patients vaccinated for HZ in each calendar year prior to biologic agent initiation and HZ incidence rate for each biologic agent. We compared HZ risks among therapies using Cox regression adjusted for potential confounders. RESULTS: Of 29,129 new biologic treatment episodes, 28.7% used abatacept, 15.9% adalimumab, 14.8% rituximab, 12.4% infliximab, 12.2% etanercept, 6.1% tocilizumab, 5.8% certolizumab, and 4.4% golimumab. The proportion of RA patients vaccinated for HZ prior to biologic agent initiation ranged from 0.4% in 2007 to 4.1% in 2011. We identified 423 HZ diagnoses with the highest HZ incidence rate for certolizumab (2.45 per 100 person-years) and the lowest for golimumab (1.61 per 100 person-years). Neither the crude incidence rate nor the adjusted hazard ratio differed significantly among biologic agents. Glucocorticoid use had a significant association with HZ. CONCLUSION: Among older patients with RA, the HZ risk was similar across biologic agents, including those with different MOAs.
OBJECTIVE: To evaluate whether the risks of herpes zoster (HZ) differed by biologic agents with different mechanisms of action (MOAs) in older rheumatoid arthritis (RA) patients. METHODS: Using Medicare data from 2006-2011, among RApatients with prior biologic agent use and no history of cancer or other autoimmune diseases, this retrospective cohort study identified new treatment episodes of abatacept, adalimumab, certolizumab, etanercept, golimumab, infliximab, rituximab, and tocilizumab. Followup started on initiation of the new biologic agent and ended at any of the following: first incidence of HZ, a 30-day gap in current exposure, death, a diagnosis of other autoimmune disease or cancer, loss of insurance coverage, or December 31, 2011. We calculated the proportion of RApatients vaccinated for HZ in each calendar year prior to biologic agent initiation and HZ incidence rate for each biologic agent. We compared HZ risks among therapies using Cox regression adjusted for potential confounders. RESULTS: Of 29,129 new biologic treatment episodes, 28.7% used abatacept, 15.9% adalimumab, 14.8% rituximab, 12.4% infliximab, 12.2% etanercept, 6.1% tocilizumab, 5.8% certolizumab, and 4.4% golimumab. The proportion of RApatients vaccinated for HZ prior to biologic agent initiation ranged from 0.4% in 2007 to 4.1% in 2011. We identified 423 HZ diagnoses with the highest HZ incidence rate for certolizumab (2.45 per 100 person-years) and the lowest for golimumab (1.61 per 100 person-years). Neither the crude incidence rate nor the adjusted hazard ratio differed significantly among biologic agents. Glucocorticoid use had a significant association with HZ. CONCLUSION: Among older patients with RA, the HZ risk was similar across biologic agents, including those with different MOAs.
Authors: Jasvinder A Singh; Daniel E Furst; Aseem Bharat; Jeffrey R Curtis; Arthur F Kavanaugh; Joel M Kremer; Larry W Moreland; James O'Dell; Kevin L Winthrop; Timothy Beukelman; S Louis Bridges; W Winn Chatham; Harold E Paulus; Maria Suarez-Almazor; Claire Bombardier; Maxime Dougados; Dinesh Khanna; Charles M King; Amye L Leong; Eric L Matteson; John T Schousboe; Eileen Moynihan; Karen S Kolba; Archana Jain; Elizabeth R Volkmann; Harsh Agrawal; Sangmee Bae; Amy S Mudano; Nivedita M Patkar; Kenneth G Saag Journal: Arthritis Care Res (Hoboken) Date: 2012-05 Impact factor: 4.794
Authors: Carlos G Grijalva; Lang Chen; Elizabeth Delzell; John W Baddley; Timothy Beukelman; Kevin L Winthrop; Marie R Griffin; Lisa J Herrinton; Liyan Liu; Rita Ouellet-Hellstrom; Nivedita M Patkar; Daniel H Solomon; James D Lewis; Fenglong Xie; Kenneth G Saag; Jeffrey R Curtis Journal: JAMA Date: 2011-11-06 Impact factor: 56.272
Authors: Ahmed M Dewedar; Medhat A Shalaby; Sulaiman Al-Homaid; Ahmed M Mahfouz; Osama A Shams; Ahmed Fathy Journal: Int J Rheum Dis Date: 2012-02-13 Impact factor: 2.454
Authors: Jie Zhang; Fenglong Xie; Elizabeth Delzell; Lang Chen; Kevin L Winthrop; James D Lewis; Kenneth G Saag; John W Baddley; Jeffrey R Curtis Journal: JAMA Date: 2012-07-04 Impact factor: 56.272
Authors: Barbara P Yawn; Robbin F Itzler; Peter C Wollan; James M Pellissier; Lina S Sy; Patricia Saddier Journal: Mayo Clin Proc Date: 2009-09 Impact factor: 7.616
Authors: Seo Young Kim; Amber Servi; Jennifer M Polinski; Helen Mogun; Michael E Weinblatt; Jeffrey N Katz; Daniel H Solomon Journal: Arthritis Res Ther Date: 2011-02-23 Impact factor: 5.156
Authors: Robin K Dore; Jenya N Antonova; Chakkarin Burudpakdee; Lawrence Chang; Magdaliz Gorritz; Mark C Genovese Journal: ACR Open Rheumatol Date: 2021-11-18
Authors: Michael Behal; Brooke Barlow; Breanne Mefford; Melissa L Thompson Bastin; J Chris Donaldson; Melanie Laine; Brittany D Bissell Journal: Crit Care Explor Date: 2021-07-13